The effects of altered apolipoprotein A-I structure on plasima HDL concentration

被引:151
作者
Sorci-Thomas, MG
Thomas, MJ
机构
[1] Wake Forest Univ, Sch Med, Dept Pathol, Baptist Med Ctr, Winston Salem, NC 27157 USA
[2] Wake Forest Univ, Sch Med, Dept Biochem, Baptist Med Ctr, Winston Salem, NC 27157 USA
关键词
D O I
10.1016/S1050-1738(01)00163-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately 46 human apolipoprotein A-I (apoA-I) coding sequence mutations have been reported to date. Roughly half of these Mutations are associated with lower than average plasma concentrations of high-density lipoprotein (HDL) apoA-I. Mutations associated with low HDL apoA-I concentrations fall into two main categories: those which poorly activate the enzyme lecithin:cholesterol acyltransferase (LCAT) and those associated with amyloidosis. These phenotypically distinct groups of mutations are uniquely localized in different regions of the apoprotein sequence. Mutations associated with abnormal LCAT activation are located within repeats 5, 6, and 7, corresponding to amino acids 121 to 186, while many of the mutations found in amyloid deposits are clustered at the amino terminus of the protein, namely residues I to 90. These observations strongly support the idea that the tertiary structure of apoA-I determines its intravascular fate and ultimately the steady state concentration of plasma HDL. (C) 2002, Elsevier Science Inc.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 66 条
[1]   Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation [J].
Amarzguioui, M ;
Mucchiano, G ;
Häggqvist, B ;
Westermark, P ;
Kavlie, A ;
Sletten, K ;
Prydz, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 242 (03) :534-539
[2]  
ARAKI K, 1994, BBA-LIPID LIPID MET, V1214, P272
[3]   A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis [J].
Asl, KH ;
Liepnieks, JJ ;
Nakamura, M ;
Parker, F ;
Benson, MD .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (02) :584-588
[4]   Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1 [J].
Asl, LH ;
Liepnieks, JJ ;
Asl, KH ;
Uemichi, T ;
Moulin, G ;
Desjoyaux, E ;
Loire, R ;
Delpech, M ;
Grateau, G ;
Benson, MD .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (01) :221-227
[5]  
ASSMANN G, 1993, CIRCULATION, V87, P28
[6]  
Bielicki JK, 1997, J LIPID RES, V38, P2314
[7]   INVIVO METABOLISM OF PROAPOLIPOPROTEIN-A-I IN TANGIER DISEASE [J].
BOJANOVSKI, D ;
GREGG, RE ;
ZECH, LA ;
MENG, MS ;
BISHOP, C ;
RONAN, R ;
BREWER, HB .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 80 (06) :1742-1747
[8]  
BOOTH DR, 1995, QJM-INT J MED, V88, P695
[9]   Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein Al gene [J].
Booth, DR ;
Tan, SY ;
Booth, SE ;
Tennent, GA ;
Hutchinson, WL ;
Hsuan, JJ ;
Totty, NF ;
Truong, O ;
Soutar, AK ;
Hawkins, PN ;
Bruguera, M ;
Caballeria, J ;
Sole, M ;
Campistol, JM ;
Pepys, MB .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (12) :2714-2721
[10]   APOLIPOPROTEIN GENETIC-VARIATION AND HUMAN-DISEASE [J].
BRESLOW, JL .
PHYSIOLOGICAL REVIEWS, 1988, 68 (01) :85-132